p53 antibodies in the sera of lung cancer patients: Comparison with p53 mutation in the tumour tissue

✍ Scribed by Christopher Paul Wild; Maaret Ridanpaa; Sisko Anttila; Richard Lubin; Thierry Soussi; Kirsti Husgafvel-Pursiainen; Harri Vainio

• Publisher: John Wiley and Sons
• Year: 1995
• Tongue: French
• Weight: 848 KB
• Volume: 64
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910640306

✦ Synopsis

Abstract

This study examined the sensitivity and specificity of serum auto‐antibodies to p53 protein as a non‐invasive marker of p53 genetic alterations or protein accumulation in lung cancer cases. A sensitive ELISA to detect serum p53 antibodies was developed and used to examine sera from 186 patients undergoing pulmonary surgery for a suspected lung cancer. Target antigens in ELISA were wild‐type p53 protein and 5 peptides covering the N‐ and C‐terminal parts of the protein. Sixteen sera were positive for serum p53 antibodies in both ELISAs and all were among the 136 patients with confirmed primary lung carcinoma. Of 50 patients with other pulmonary diseases, none had p53 antibodies. In 92 cancer patients exons 5 to 8 of the p53 gene were examined for mutations by denaturing gradient gel electrophoresis and direct sequencing of PCR products. Forty‐seven tumours had a p53 mutation and 7 (15.2%) of these were positive for p53 antibodies. Two patients had serum antibodies but no detectable mutation in exons 5 to 8. Frequencies of p53 mutations and serum antibodies were higher in squamous cell carcinoma patients than in adenocarcinoma. Accumulation of p53 protein in tumour tissue was observed in 32 patients, but only 5 were positive for p53 antibodies. In conclusion, serum p53 antibodies were detected only in a proportion of lung cancer cases, but the majority were specifically associated with a detectable p53 mutation in the tumour. © 1995 Wiley‐Liss, Inc.